# Regeneron Pharmaceuticals, Inc. – Consensus ‘buy’ rating and 19.9% Upside Potential

- Link: https://www.directorstalkinterviews.com/regeneron-pharmaceuticals-inc.consensus-buy-rating-and-19.9-upside-potential/4121175124
- Published: 2024-10-23T15:04:51+01:00
- Author: Charlotte Edwards

**Regeneron Pharmaceuticals, Inc.** which can be found using ticker (REGN) now have
24 confirmed analysts covering the stock with the consensus suggesting a rating 
of ‘buy’. The range between the high target price and low target price is between
$1,300.00 and $820.00 calculating the mean target price we have $1,161.45. Given
that the stocks previous close was at $968.50 this indicates there is a potential
upside of 19.9%. The 50 day MA is $1,102.08 and the 200 day MA is $1,013.76. The
market capitalization for the company is 106.08B. The price for the stock stands
currently at: $962.34 USD

 The potential market cap would be $127,218,108,621 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 25.48, revenue per share of $125.83
and a 7.61% return on assets.

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers,
invents, develops, manufactures, and commercializes medicines for serious diseases.
Its commercialized medicines and product candidates in development are designed 
to help patients with eye diseases, allergic and inflammatory diseases, cancer, 
cardiovascular and metabolic diseases, pain, hematologic conditions, infectious 
diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection,
Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab)
Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza(
evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection,
ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept)
Injection for Intravenous Infusion. The Company also provides Expresse service assurance
and CloudCheck WiFi experience management solutions.

Share on: